Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation ( residents ofhospital and treatment cen...)

Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation

residents of hospital and treatment centers whose immune systems are battered by age, disease or myelosuppressive medications.

The paper was published as Scott, M.G. et al. (2007) "An anti-infective peptide that selectively modulates the innate immune response" in Nature Biotechnology (April 2007, vol. 25 No. 4) and will be accessible online on March 25.

About Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first-in-class drugs that selectively trigger the body's innate defenses without causing inflammation. IDRs have major market potential for infectious diseases, cancer and inflammatory disease. Inimex's investors include BDC Venture Capital, Canadian Medical Discovery Fund, Growthworks Capital, Discovery Capital and BC Advantage Fund. For more information, visit http://www.inimexpharma.com.

    Noonan Russo

    Andrew Villani or David Schull

    212-845-4262

andrew.villani@eurorscg.com david.schull@eurorscg.com

CONTACT: Andrew Villani, , or David Schull,, both of Noonan Russo, +1-212-845-4262, forInimex Pharmaceuticals Inc. andrew.villani@eurorscg.com david.schull@eurorscg.com

Web site: http://www.inimexpharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Page: 1 2
Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
5. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. PromegaExpress Expands Easy Access to Products with New Cabinet
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
10. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

Post Your Comments:

(Date:12/4/2009)... Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today ... the company,s Phase II-b, dose escalation, clinical trial in ... injury (TBI). Oxycyte is the Company,s perfluorocarbon (PFC) therapeutic ... in improving the outcome of patients with severe TBI. ...

(Date:12/4/2009)... Chemistry World recently highlighted a new ... of America ( PhRMA ) that identifies 97 new ... ,, The report found that the 97 products ... are either in human clinical trials or awaiting approval by ...

(Date:12/4/2009)... DIEGO, Calif., Dec. 4 Suneva Medical, a privately-held ... Philip Ranker as Vice President and Chief Financial Officer. ... Suneva Medical,s general and administrative functions including finance, accounting, ... also serve on the Company,s senior management team. ...

Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2 U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4 Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 51001 1 Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 51001 2 Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 51001 3 Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 51001 4 Spa Chefs Prepare You for a Healthy Summer 50996 1 Spa Chefs Prepare You for a Healthy Summer 50996 2 New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 1 New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 2 New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 3 New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 4 New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 5 New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 6

[0] Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland [0] U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS [0] Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer

... Blood Pressure ... Accelerates, ... manufacturer of the RESPeRATE(R) hypertension treatment,device, clinically-proven to significantly lower blood ... holiday,season. This milestone marks a period of widespread consumer adoption and,physician ...

... -- Recommendation based on study results demonstrating survival advantage ... of 18.4 months when added to standard therapy, ... of care, BOULDER, Colo., Jan. 24 Pharmion Corporation,(Nasdaq: ... (EMEA),has issued a positive opinion to recommend approval of Thalidomide,Pharmion(R) ...

Other Medicine Technology:InterCure Announces 100,000th RESPeRATE Unit Sold 2 InterCure Announces 100,000th RESPeRATE Unit Sold 3 Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2 Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3 Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4 Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5 Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6

InterCure Announces 100,000th RESPeRATE Unit Sold Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency

(Date:12/6/2009)... ORLEANS, Dec. 6 Sickle cell disease, ... blood cells, is one of the most common ... the world, including more than 70,000 Americans.(1) Research ... the American Society of Hematology highlights intriguing studies ... presents for children with this blood disorder, evaluations ...

(Date:12/6/2009)... Joseph W. Belluck of Belluck & Fox, LLP says dangerous substances ... seasons. , ... New York, NY (PRWEB) December 6, ... season, they should be alert to reports of recalls due to ... lawyer., , ,“Close to 230,000 children visit hospital emergency rooms each ...

(Date:12/5/2009)... Blood Cancer Is Most Challenging-- ,, PHILADELPHIA ... identified specific genes, dubbed partner genes, that fuse with ... in infants. By more accurately defining specific partner genes, ... from particular treatments. ,, Oncologists also aim to ...

(Date:12/5/2009)... of International Solutions, an innovative new international private medical insurance plan ... addition to offering customers the flexibility to add or remove a ... Solutions enables customers to tailor their benefits to complement those already ... ...

(Date:12/4/2009)... YORK, Dec. 4 Thousands of KPMG LLP employees came ... in a community service event which combines the audit, tax ... ,, "This national service day reflects our firm,s long history ... the spirit of caring to brighten the holidays for some ...

[0] Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease [0] Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season [0] New Gene Findings Will Help Guide Treatment in Infant Leukemia [0] AVIVA's Private Health Insurance Products Solutions Go International [0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children

... similarly in all treatment, groups, , ... /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; ... analysis for the Phase II RADICAL study (Reduced Fluence ... study is a Phase II, multicenter, randomized, single-masked study ...

... The nation,s largest union of,registered nurses today ... Senator Mitch McConnell for his Grinch-like efforts to ... auto workers accept devastating,and punitive cuts in wages ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081216/AQTU036 ), ...

... efficiently, Fresho.com offers bulk job posting and announces new job ad distribution ... ... (PRWEB) December 16, 2008 -- In order to help employers fill their ... engine Fresho.com now offers employers to submit their job openings to ...

... multispecialty medical group in Southern California, announced the opening of its ... Monrovia. , ... Torrance, CA (PRWEB) December 16, 2008 ... Southern California, announced the opening of its newest medical office ...

... BLOOMINGTON, Ind. -- The landmark "Sexual Behavior in the ... and orientation -- without even using the word "bisexual" ... pioneering sex researcher Alfred Kinsey and his research team ... unveiled the seven-point Heterosexual-Homosexual Rating Scale, commonly known as ...

... of widely used approach, experts say , , MONDAY, Dec. ... cancer -- cancer that has spread beyond the wall ... long-term hormone treatment cut their risk of dying in ... of radiotherapy kept patients healthy much longer, the Swedish ...

Other Medicine News:Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 2 Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 3 Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 4 Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 5 Health News:'The Mitch Who Stole Christmas' 2 Health News:Fresho.Com Offers Efficient Job Postings for Employers and Recruiters 2 Health News:HealthCare Partners Opens a New Medical Office in Monrovia, CA 2 Health News:Indiana University researchers revisit male bisexuality 2 Health News:Indiana University researchers revisit male bisexuality 3 Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 2 Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 3

QLT announces interim results of radical study evaluating Visudyne combination therapy 'The Mitch Who Stole Christmas'Fresho.Com Offers Efficient Job Postings for Employers and Recruiters HealthCare Partners Opens a New Medical Office in Monrovia, CA Indiana University researchers revisit male bisexuality Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

Medicine Products:

Rh Factor Reticulocytes, Percent & Number Respiratory Viruses DFA Respiratory Syncytial Virus Antibody, IgM

( residents ofhospital and treatment cen...)Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation,Health